Risk and prognosis of second primary malignancies in patients with follicular lymphoma in the era of rituximab: A population study based on the SEER database
机构:[1]Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Chengdu, China.四川大学华西医院[2]Department of Pediatric Gastroenterology, Lanzhou University Second Hospital, Lanzhou, China.[3]No. 37 Guoxue Xiang, District Wuhou, Chengdu, Sichuan, China[4]82 Cuiyingmen Street, Chengguan District, Lanzhou, Gansu Province, China
Caigang Xu received funding from Sichuan Science and Technology Department for Key Research and Development Program (2019YFS0027).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类|3 区综合性期刊
小类|3 区综合性期刊
最新[2025]版:
大类|3 区综合性期刊
小类|3 区综合性期刊
第一作者:
第一作者机构:[1]Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Chengdu, China.[3]No. 37 Guoxue Xiang, District Wuhou, Chengdu, Sichuan, China
推荐引用方式(GB/T 7714):
Tian Ying,Yang Wanxi,Xu Juan,et al.Risk and prognosis of second primary malignancies in patients with follicular lymphoma in the era of rituximab: A population study based on the SEER database[J].Plos One.2025,20(5):e0324532.doi:10.1371/journal.pone.0324532.
APA:
Tian Ying,Yang Wanxi,Xu Juan,Li Yuanxiao,Tang Wenjiao&Xu Caigang.(2025).Risk and prognosis of second primary malignancies in patients with follicular lymphoma in the era of rituximab: A population study based on the SEER database.Plos One,20,(5)
MLA:
Tian Ying,et al."Risk and prognosis of second primary malignancies in patients with follicular lymphoma in the era of rituximab: A population study based on the SEER database".Plos One 20..5(2025):e0324532